LA Improves the Prognosis of Patients With ICVD After Surgery

Huaqiu Zhang

Status: Not yet enrolling

Conditions: Ischemia; Cerebrovascular; Cognitive Impairment

Treatments: Dietary Supplement: Lactobacillus acidophilus

Study type: Interventional

Funder types: Other

Identifiers

NCT05656209

13419632963

Details and patient eligibility

About

Ischemic cerebrovascular disease will cause serious harm to the life and safety of patients, and the treatment prognosis is poor. Numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. We have previously found that Lactobacillus acidophilus administration could improve cognitive impairment in MCAO and BCAS mice. Therefore, Based on the above research background and the basis of previous studies, we believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the "brain-gut axis".

Full description

Ischemic cerebrovascular disease, as a common form of stroke, is one of the main causes of global morbidity and mortality. The mortality rate of this disease is relatively high, and the treatment prognosis is poor, which will cause serious harm to the life and safety of patients. The optimal treatment for ischemic cerebrovascular disease is still unclear, and the effects of different treatments are still controversial. Therefore, it is of great clinical significance to explore a safe and simple adjuvant treatment method to help patients recover their nervous system function faster and better.

At present, numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. Adding intestinal probiotics can improve the intestinal flora distribution, and significantly improve cognitive function in elderly patients with mild cognitive impairment and prevention of brain atrophy. Lactobacillus acidophilus is rich in short chain fatty acids (SCFA). Clinical studies have shown that SCFA levels are negatively correlated with the severity and prognosis of ischemic stroke. Numerous studies have demonstrated that the intestinal supply short chain fatty acids can improve cognitive function, in the middle cerebral artery occlusion (MCAO) induced by acute cerebral ischemia model, rich in the intestines of SCFA can cure acute cerebral ischemia in mice induced by nerve injury. More importantly, in mice with acute cerebral ischemia induced by middle cerebral artery occlusion (MCAO) and chronic cerebral ischemia caused by bilateral common carotid artery stenosis (BCAS), we have previously found that mice have cognitive impairment, accompanied by intestinal flora dysregulation.

Lactobacillus acidophilus administration has a significant effect on improving cognitive function. Based on the above research background and the basis of previous studies, the researchers believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the "brain-gut axis", and increase the reliability and scope of revascularization, and ultimately improve the prognosis of patients with ischemic cerebrovascular disease.

Enrollment: 236 estimated patients

Sex: All

Ages: 35 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. 35-60 years old;
2. Diagnosed as ischemic cerebrovascular disease, mild to moderate symptoms, can independently complete the neuropsychological test;
3. No previous operation history;
4. The modified Rankin scale score was 0 or 1;
5. Carotid artery ischemic symptoms ≤3 months before treatment;
6. Surgical treatment;

Exclusion criteria

1. Previous dementia;
2. hearing or visual impairment;
3. drugs that may or are known to affect cognitive abuse;
4. alcohol addiction;
5. Diagnosis of depression, schizophrenia and other mental diseases;
6. MRI showed severe cerebral infarction;
7. Patients with Lactobacillus acidophilus allergy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

236 participants in 2 patient groups

Control group

No Intervention group

Description:

The patient received conventional care after surgery, with no other interventions.

LA treatment group

Experimental group

Description:

The patient received conventional treatment and Lactobacillus acidophilus treatment for three months after surgery.

Treatment:

Dietary Supplement: Lactobacillus acidophilus